Showing 161-170 of 9754 results for "".
Long-Term Effects of Neuromodulators on Aging
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/long-term-effects-of-neuromodulators-on-aging/18810/Shannon Humphrey, MD discusses the cumulative anti-aging benefits of long-term treatments with botulinum toxin type A. She shares her observations from the bench and offers a review of what the literature shows to support her recommendation for regular conservative neuromodulator treatments to improAlma Lasers Dye-PL Applicator for the HarmonyXL Platform
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/alma-lasers-dye-pl-applicator-for-the-harmonyxl-platform-/19243/Dye-PL is a new pulsed light applicator from Alma Lasers that concentrates the wavelength into a narrow filter of 100 nm, providing Dye Laser results, with the safety and efficiency of light.Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.DermWireTV: Zilxi Launch, Eczema Awareness, Uninsurance Rates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-zilxi-launch-eczema-awareness-uninsurance-rates/19863/For eczema awareness month, the National Eczema Association (NEA) is offering virtual educational programs, community engagement activities, and additional free resources. Georgia, Oklahoma, and Texas have the highest rates of uninsurance. Zilxi minocycline topical foam launches as new data fromDermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-acneally-launches-rosacea-insights-mc2epi-collaboration/19849/Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasisSkin Cancer Awareness, Epiduo Data, Impoyz Launch
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-skin-cancer-awareness-epiduo-data-impoyz-launch/18307/Data shed light on patents' attitudes towards kids' sunblock and new findings emerge on melanoma risks. FDA accepts BLA for cemiplimab for advanced SCC and approves Novartis' Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutationsLaser Advice for Early Adopters
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-advice-for-early-adopters/18809/“Fat melting is not a passing phase,” says Amy Forman Taub, MD. The technology is in its infancy, but applications will expand, she says. Dr. Taub, a laser and device expert offers suggestions on evaluating and choosing devices for a cosmetic practice. GenerationsHoya ConBio - Laser Assisted Hair Reduction
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-laser-assisted-hair-reduction/19461/Video demonstrations on the different settings to use for laser assisted hair reduction.Part 3, 1726 nm lasers: How to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is to be patient
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24341/Chapter 3 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is toDermWireTV: Olumiant Approved for AA; Radiesse + Launch; Derms as Influencers; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-olumiant-approved-for-aa-radiesse-launch-derms-as-influencers-vcs/20107/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. Dermatologists rank as top influencers of consumers’ decisions to have cosmetic procedures, according to results of the American Society for Dermatologic Surgery (ASDS) Consumer Survey